(0.01%) 5 517.50 points
(0.12%) 39 893 points
(0.04%) 19 759 points
(-0.04%) $81.60
(0.43%) $2.82
(-0.25%) $2 338.50
(0.12%) $29.56
(0.55%) $1 007.30
(0.11%) $0.932
(-0.08%) $10.52
(0.01%) $0.788
(-0.85%) $87.25
-85.71% $ 0.000100
Live Chart Being Loaded With Signals
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient\'s CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient\'s tumor...
Stats | |
---|---|
Dzisiejszy wolumen | 30 268 |
Średni wolumen | 80 568 |
Kapitalizacja rynkowa | 0.00 |
EPS | $-0.230 ( Q1 | 2022-05-05 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00700 (1 166.67%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-06-02 | Duvall Diantha | Sell | 1 355 | Common Stock |
2022-06-02 | Flechtner Jessica Baker | Sell | 1 578 | Common Stock |
2022-06-02 | Clark William D | Sell | 4 023 | Common Stock |
2022-06-01 | Sumer Jacquelyn L | Sell | 2 500 | Common Stock |
2022-05-31 | Clark William D | Sell | 117 244 | Common Stock |
INSIDER POWER |
---|
0.00 |
Last 92 transactions |
Buy: 40 896 126 | Sell: 84 760 217 |
Wolumen Korelacja
Genocea Biosciences, Inc. Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Genocea Biosciences, Inc. Korelacja - Waluta/Towar
Genocea Biosciences, Inc. Finanse
Annual | 2021 |
Przychody: | $1.64M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-0.480 |
FY | 2021 |
Przychody: | $1.64M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-0.480 |
FY | 2020 |
Przychody: | $1.36M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-0.980 |
FY | 2019 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-1.890 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Genocea Biosciences, Inc.
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient\'s CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient\'s tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej